Krystal Biotech Inc. plans to raise up to $35 million in an initial public offering, according to a Securities and Exchange Commission filing late Monday. The Pittsburgh-based gene therapy company is a developer of treatments for dermatological diseases. With no revenue, Krystal reported a net loss of $1.2 million, or $5.89 a share, for 2016. Ladenburg Thalmann & Co. was listed as the underwriter for the IPO. Krystal intends to list on the Nasdaq under the ticker symbol “KRYS.”
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Latest posts by Market Watch (see all)
- The Wall Street Journal: Merkel wins in Germany, but anti-immigrant party enters parliament with huge gains - September 24, 2017
- White House imposes new travel restrictions against 8 countries, including Venezuela - September 24, 2017
- Sexual harassment in the workplace isn’t just perpetrated by co-workers or the boss - September 24, 2017